Adaptive Biotechnologies Corp (NASDAQ: ADPT) is 22.77% higher on its value in year-to-date trading and has touched a low of $2.56 and a high of $9.01 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ADPT stock was last observed hovering at around $7.61 in the last trading session, with the day’s loss setting it -0.25%.
Currently trading at $7.36, the stock is -3.39% and -5.47% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.99 million and changing -3.29% at the moment leaves the stock 20.63% off its SMA200. ADPT registered 183.08% gain for a year compared to 6-month gain of 65.39%. The firm has a 50-day simple moving average (SMA 50) of $7.7863 and a 200-day simple moving average (SMA200) of $6.10155.
The stock witnessed a -0.94% loss in the last 1 month and extending the period to 3 months gives it a -4.54%, and is -0.27% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.10% over the week and 8.99% over the month.
Adaptive Biotechnologies Corp (ADPT) has around 619 employees, a market worth around $1.09B and $178.96M in sales. Profit margin for the company is -89.12%. Distance from 52-week low is 187.50% and -18.31% from its 52-week high. The company has generated returns on investments over the last 12 months (-38.50%).
with sales reaching $42.13M over the same period.The EPS is expected to grow by 14.68% this year, but quarterly earnings will post 18.85% year-over-year. Quarterly sales are estimated to grow 0.60% in year-over-year returns.
287.0 institutions hold shares in Adaptive Biotechnologies Corp (ADPT), with institutional investors hold 96.34% of the company’s shares. The shares outstanding are 147.77M, and float is at 141.74M with Short Float at 6.98%. Institutions hold 94.03% of the Float.
The top institutional shareholder in the company is VIKING GLOBAL INVESTORS LP with over 29.99 million shares valued at $108.58 million. The investor’s holdings represent 20.3466 of the ADPT Shares outstanding. As of 2024-06-30, the second largest holder is RUBRIC CAPITAL MANAGEMENT LP with 14.0 million shares valued at $50.68 million to account for 9.4971 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 11.66 million shares representing 7.9124 and valued at over $42.22 million, while MATRIX CAPITAL MANAGEMENT COMPANY, LP holds 7.8504 of the shares totaling 11.57 million with a market value of $41.89 million.
Adaptive Biotechnologies Corp (ADPT) Insider Activity
The most recent transaction is an insider sale by ROBINS HARLAN S, the company’s Chief Scientific Officer. SEC filings show that ROBINS HARLAN S sold 1,698 shares of the company’s common stock on Mar 24 ’25 at a price of $9.00 per share for a total of $15282.0. Following the sale, the insider now owns 1.28 million shares.
Still, SEC filings show that on Mar 13 ’25, GRIFFIN MICHELLE RENEE (Director) disposed off 36,291 shares at an average price of $7.19 for $0.26 million. The insider now directly holds 15,394 shares of Adaptive Biotechnologies Corp (ADPT).
